Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

In connection with the discontinuation of development of tesetaxel, Joseph O'Connell, M.D. mutually agreed with Odonate to terminate his employment effective July 31, 2021. Dr. O'Connell had served as Odonate's Chief Medical Officer. Dr. O'Connell will be entitled to receive aggregate salary continuation payments of $321,670, payable over the 10-month period following his separation date. The Company will also pay for Dr. O'Connell's medical coverage for up to 12 months following his separation date. Such severance benefits are conditioned on his entry into and compliance with a separation and general release agreement.

Item 9.01 Financial Statements and Exhibits



(d) Exhibits



 Exhibit
   No.                                   Description

104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses